Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT02129985

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02129985
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02129985. Randomized; no masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy
Acronym
T2DMRS
Intervention (Drug)
Exenatide
Intervention (Drug)
Metformin
Lead sponsor
xiaolong zhao (class: other)
Collaborator
Shanghai Zhongshan Hospital (class: other)
Collaborator
The third people's Hospital Affiliated to Shanghai Jiao Tong University (class: not stated)
Collaborator
Second Affiliated Hospital of Soochow University (class: other)
Collaborator
The First Hospital of Guiyang Medical college (class: not stated)
Collaborator
Fuling Central Hospital of Chongqing City (class: other)
Collaborator
Taizhou Hospital (class: other)
Collaborator
Shanghai Pudong New Area Gongli Hospital (class: other)

Record details

Record id
cardio:ct-nct02129985
Content hash
6df9fe033696ed7970e24ef327c3b37969aba054735adc27ba362ef259eb23e4